|
1
|
Hanahan D, Lanzavecchia A and Mihich E:
Fourteenth Annual Pezcoller Symposium: the novel dichotomy of
immune interactions with tumors. Cancer Res. 63:3005–3008.
2003.PubMed/NCBI
|
|
2
|
Oliveira-Neto HH, Leite AF, Costa NL, et
al: Decrease in mast cells in oral squamous cell carcinoma:
possible failure in the migration of these cells. Oral Oncol.
43:484–490. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akbar AN, Taams LS, Salmon M and
Vukmanovic-Stejic M: The peripheral generation of CD4+
CD25+ regulatory T cells. Immunology. 109:319–325. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang HY, Lee DA, Peng G, et al:
Tumor-specific human CD4+ regulatory T cells and their ligands:
implications for immunotherapy. Immunity. 20:107–118. 2004.
|
|
5
|
Wei WZ, Morris GP and Kong YC: Anti-tumor
immunity and autoimmunity: a balancing act of regulatory T cells.
Cancer Immunol Immunother. 53:73–78. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang RF: Regulatory T cells and innate
immune regulation in tumor immunity. Springer Semin Immunopathol.
28:17–23. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamaguchi T and Sakaguchi S: Regulatory T
cells in immune surveillance and treatment of cancer. Semin Cancer
Biol. 16:115–123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen L: Co-inhibitory molecules of the
B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol.
4:336–347. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen W, Jen W, Hardegen N, et al:
Conversion of peripheral CD4+ CD25 naive T cells to
CD4+ CD25+ regulatory T cells by TGF-β
induction of transcription factor FoxP3. J Exp Med. 198:1875–1886.
2003.
|
|
10
|
Hurwitz AA, Yu TF, Leach DR and Allison
JP: CTLA-4 blockade synergizes with tumor-derived
granulocyte-macrophage colony-stimulating factor for treatment of
an experimental mammary carcinoma. Proc Natl Acad Sci USA.
95:10067–10071. 1998. View Article : Google Scholar
|
|
11
|
Hurwitz AA, Foster BA, Kwon ED, et al:
Combination immunotherapy of primary prostate cancer in a
transgenic mouse model using CTLA-4 blockade. Cancer Res.
60:2444–2448. 2000.PubMed/NCBI
|
|
12
|
Tartour E, Mosseri V, Jouffroy T, et al:
Serum soluble interleukin-2 receptor concentrations as an
independent prognostic marker in head and neck cancer. Lancet.
357:1263–1264. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jones E, Dahm-Vicker M, Simon AK, et al:
Depletion of CD25+ regulatory cells results in
suppression of melanoma growth and induction of autoreactivity in
mice. Cancer Immun. 2:1–12. 2002.
|
|
14
|
Phan GQ, Yang JC, Sherry RM, et al: Cancer
regression and autoimmunity induced by cytotoxic T
lymphocyte-associated antigen 4 blockade in patients with
metastatic melanoma. Proc Natl Acad Sci USA. 100:8372–8377. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Curiel TJ, Coukos G, Zou L, et al:
Specific recruitment of regulatory T cells in ovarian carcinoma
fosters immune privilege and predicts reduced survival. Nat Med.
10:942–949. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ghaderi A, Yeganeh F, Kalantari T, et al:
Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast
Cancer Res Treat. 86:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolf D, Wolf AM, Rumpold H, et al: The
expression of the regulatory T cell-specific forkhead box
transcription factor FoxP3 is associated with poor prognosis in
ovarian cancer. Clin Cancer Res. 11:8326–8331. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hiraoka N, Onozato K, Kosuge T and
Hirohashi S: Prevalence of FoxP3+ regulatory T cells
increases during the progression of pancreatic ductal
adenocarcinoma and its premalignant lesions. Clin Cancer Res.
12:5423–5434. 2006.
|
|
19
|
Larkin J, Tangney M, Collins C, et al:
Oral immune tolerance mediated by suppressor T cells may be
responsible for the poorer prognosis of foregut cancers. Med
Hypotheses. 66:541–544. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Downey SG, Klapper JA, Smith FO, et al:
Prognostic factors related to clinical response in patients with
metastatic melanoma treated by CTL-associated antigen-4 blockade.
Clin Cancer Res. 13:6681–6688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fecci PE, Ochiai H, Mitchell DA, et al:
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the
CD4+ T cell compartment without affecting regulatory
T-cell function. Clin Cancer Res. 13:2158–2167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu J, Xu D, Liu Z, et al: Increased
regulatory T cells correlate with CD8 T-cell impairment and poor
survival in hepatocellular carcinoma patients. Gastroenterology.
132:2328–2339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miracco C, Mourmouras V, Biagioli M, et
al: Utility of tumour-infiltrating CD25+
FoxP3+ regulatory T cell evaluation in predicting local
recurrence in vertical growth phase cutaneous melanoma. Oncol Rep.
18:1115–1122. 2007.PubMed/NCBI
|
|
24
|
Strauss L, Bergmann C and Whiteside TL:
Functional and phenotypic characteristics of D4+
CD25-high FoxP3+ Treg clones obtained from peripheral
blood of patients with cancer. Int J Cancer. 121:2473–2483.
2007.PubMed/NCBI
|
|
25
|
Chikamatsu K, Sakakura K, Whiteside TL and
Furuya N: Relationships between regulatory T cells and
CD8+ effector populations in patients with squamous cell
carcinoma of the head and neck. Head Neck. 29:120–127.
2007.PubMed/NCBI
|
|
26
|
Loose D, Signore A, Bonanno E, et al:
Prognostic value of CD25 expression on lymphocytes and tumor cells
in squamous-cell carcinoma of the head and neck. Cancer Biother
Radiopharm. 23:25–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bai XF, Liu J, May KF Jr, Guo Y, Zheng P
and Liu Y: B7-CTLA4 interaction promotes cognate destruction of
tumor cells by cytotoxic T lymphocytes in vivo. Blood.
99:2880–2889. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, Ioan-Facsinay A, van der Voort EI,
Huizinga TW and Toes RE: Transient expression of FoxP3 in human
activated nonregulatory CD4+ T cells. Eur J Immunol.
37:129–138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng Y and Rudensky AY: Foxp3 in control
of the regulatory T cell lineage. Nat Immunol. 8:457–462. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Badoual C, Hans S, Rodriguez J, et al:
Prognostic value of tumor-infiltrating CD4+ T-cell
subpopulations in head and neck cancers. Clin Cancer Res.
12:465–472. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Böheim K, Denz H, Böheim C, Glassl H and
Huber H: An immunohistologic study of the distribution and status
of activation of head and neck tumor infiltrating leukocytes. Arch
Otorhinolaryngol. 244:127–132. 1987.PubMed/NCBI
|
|
32
|
Antunes JLF, Biazevic MGH, de Araujo ME,
Tomita NE, Chinellato LEM and Narvai PC: Trends and spatial
distribution of oral cancer mortality in São Paulo, Brazil,
1980–1998. Oral Oncol. 37:345–350. 2001.
|
|
33
|
Vartanian JG, Carvalho AL, Filho MJA,
Júnior MH, Magrin J and Kowalski LP: Predictive factors and
distribution of lymph node metastasis in lip cancer patients and
their implications on the treatment of the neck. Oral Oncol.
40:223–227. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wong YK, Chang KW, Cheng CY and Liu CJ:
Association of CTLA-4 gene polymorphism with oral squamous cell
carcinoma. J Oral Pathol Med. 35:51–54. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ke X, Wang J, Li L, Chen IH, Wang H and
Yang XF: Roles of CD4+xCD25(high) FoxP3+
Tregs in lymphomas and tumors are complex. Front Biosci.
13:3986–4001. 2008.
|
|
36
|
Schwarz S, Butz M, Morsczeck C, Reichert
TE and Driemel O: Increased number of CD25 FoxP3 regulatory T cells
in oral squamous cell carcinomas detected by chromogenic
immunohistochemical double staining. J Oral Pathol Med. 37:485–489.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cho Y, Miyamoto M, Kato K, et al:
CD4+ and CD8+ T cells cooperate to improve
prognosis of patients with esophageal squamous cell carcinoma.
Cancer Res. 63:1555–1559. 2003.
|
|
38
|
Bromwich EJ, McArdle PA, Canna K, et al:
The relationship between T-lymphocyte infiltration, stage, tumour
grade and survival in patients undergoing curative surgery for
renal cell cancer. Br J Cancer. 89:1906–1908. 2003. View Article : Google Scholar
|
|
39
|
Agarwal A, Rani M, Saha GK, et al:
Disregulated expression of the Th2 cytokine gene in patients with
intraoral squamous cell carcinoma. Immunol Invest. 32:17–30. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ebert LM, Tan BS, Browning J, et al: The
regulatory T cell-associated transcription factor FoxP3 is
expressed by tumor cells. Cancer Res. 68:3001–3009. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Karanikas V, Speletas M, Zamanakou M, et
al: FoxP3 expression in human cancer cells. J Transl Med. 6:19–24.
2008. View Article : Google Scholar : PubMed/NCBI
|
